Breast biomarkers evolution between primary and distant metastasis: incidence and significance
Histopathology · 2025
DOI: 10.1111/his.15387 ↗Kurz gefasst
Fachartikel in der Zeitschrift Histopathology, 2025. Verfasst von Maha Khedr und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Aims
To evaluate the evolution when breast cancer (BC) is classified as three clinical profiles and five clinical profiles by incorporating human epidermal growth factor 2 (HER2)‐low to the biomarkers’ profile. Methods and results BC with distant metastasis that has document hormonal receptors (HR) (positive, negative) and HER2 (positive, low, zero) results were included ( n = 161). Cases were categorised into three clinical profiles (HR‐positive/HER2‐negative, HER2‐positive and TNBC) and five (HR‐positive/HER2‐zero, HR‐positive/HER2‐low, HR‐negative/HER2‐zero, HR‐negative/HER2‐low, HR‐positive or negative/HER2‐positive). Evolution occurred in 22.4% cases when three clinical profiles were analysed and 36.6% considering five clinical profiles. There were no statistically significant differences among the three clinical profiles in overall survival (OS). When five clinical profiles were analysed, HR‐negative/HER2‐zero had the worst OS with HzR = 6.82 and 95% confidence interval (CI) =1.19, 39.23, P = 0.031. In the multivariable analysis, ER‐positive was associated with HER2 discordance less than oestrogen receptor (ER)‐negative with odds ratio (OR) = 0.354 and 95% CI = 0.14–0.88, P = 0.025. In the multivariable analysis, patients with Eastern Cooperative Oncology Group 2+ had worse OS with hazard ratio (HzR) = 5.54 and 95% CI = 2.4–12.79, P < 0.0001. HR concordant had better OS with HzR = 0.34 and 95% CI = 0.2–0.63, P = 0.0004. HER2 conversion from low to zero had worse OS than HER2 concordance with HzR 2.66 and 95% CI = 1.21–5.83, P = 0.015.
Conclusions
Five‐profile classification provides a more accurate idea about the rate of potential change in treating BC in the metastatic setting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
- Department of Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
- Department of Biostatistics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA.
ORCID-Profile: Maha Khedr, Shipra Gandhi, Arya Mariam Roy, Malak Alharbi, Anthony George, Kristopher Attwood, Thaer Khoury
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Khedr, M., Gandhi, S., Roy, A. M., Alharbi, M., George, A., Attwood, K., & Khoury, T. (2025). Breast biomarkers evolution between primary and distant metastasis: incidence and significance. Histopathology. https://doi.org/10.1111/his.15387
Vancouver
Khedr M, Gandhi S, Roy AM, Alharbi M, George A, Attwood K, et al. Breast biomarkers evolution between primary and distant metastasis: incidence and significance. Histopathology. 2025. doi:10.1111/his.15387
BibTeX
@article{Khedr2025,
author = {Khedr, Maha and Gandhi, Shipra and Roy, Arya Mariam and Alharbi, Malak and George, Anthony and Attwood, Kristopher and Khoury, Thaer},
title = {Breast biomarkers evolution between primary and distant metastasis: incidence and significance},
journal = {Histopathology},
year = {2025},
doi = {10.1111/his.15387}
}
EUVIMED